5,436
Participants
Start Date
June 6, 2024
Primary Completion Date
September 30, 2028
Study Completion Date
December 31, 2028
Apixaban 2.5 MG
To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation
RECRUITING
Helsinki University Hospital, Helsinki
Collaborators (2)
Helsinki University Central Hospital
OTHER
University of Helsinki
OTHER
University College, London
OTHER
Population Health Research Institute
OTHER
Tabriz University of Medical Sciences
OTHER
Tampere University Hospital
OTHER
Turku University Hospital
OTHER_GOV
Oulu University Hospital
OTHER
North Karelia Central Hospital
OTHER
Albany Medical College
OTHER
PaijatHame Central Hospital
OTHER
Clinical Urology and Epidemiology Working Group
OTHER_GOV